Subtenons vs. Intravitreal Triamcinolone in Refractory Diabetic Macular Oedema
Indira Moorthy Madgula. 2A Fellsdyke Court, Gateshead, NE10 9SB.Tel.: 0044 07832212783; fax: 0044 01482 605327; e-mail: email@example.com
Diabetic macular oedema has been treated with triamcinolone acetonide (TA) with varying results. The study aimed to compare the effectiveness of intravitreal vs. posterior subtenons injection of TA for treatment of refractory diabetic macular oedema.
Method: Twelve patients received 40 mg of subtenons triamcinolone (STA) and 15 received 4 mg of intravitreal triamcinolone (IVTA).
Results: IVTA and STA groups demonstrated a reduction in macular thickness of 48.4% and 12.4%, respectively, at 1 month. IVTA eyes remained statistically thinner at 3 months but not at 6 months. In the IVTA group, 50% had an improved visual acuity and 35.7% a stable visual acuity. Vision improved in 33.3% of patients in STA group and remained stable in 50%. Change in visual acuity was not statistically significant between the two groups.
Conclusion: This study does not advocate the superiority of one route of administration of TA over another and recommends randomised control trials to establish best practise in this field.
Key messages: Intravitreal and subtenons triamcinolone are equally effective in transiently improving vision in refractory diabetic macular oedema.